Status:
COMPLETED
Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization
Lead Sponsor:
Hanane EL KENZ
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Cau...
Eligibility Criteria
Inclusion
- Sickle cell disease patients treated within the CHU Brugmann or Queen Fabiola Children's Hospital
Exclusion
- None
Key Trial Info
Start Date :
February 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2020
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT03405402
Start Date
February 13 2018
End Date
August 3 2020
Last Update
January 28 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020
2
HUDERF
Brussels, Belgium, 1020